A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Patients With Severe Hypertension (Grade III)
Phase of Trial: Phase III
Latest Information Update: 03 Jan 2018
At a glance
- Drugs Esaxerenone (Primary)
- Indications Hypertension
- Focus Therapeutic Use
- Sponsors Daiichi Sankyo Company
- 31 Mar 2017 Status changed from active, no longer recruiting to completed.
- 14 Feb 2017 Planned End Date changed from 1 Dec 2017 to 31 Dec 2017.
- 14 Feb 2017 Status changed from recruiting to active, no longer recruiting.